Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO) has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. The company's management will engage in a fireside chat on Tuesday, December 3, 2024, at 9:10 a.m. ET. The presentation will be accessible through a live webcast via the investor relations section of Akero's website at www.akerotx.com, with an archived replay available afterward. Akero is a clinical-stage company focused on developing treatments for serious metabolic diseases with high unmet medical needs.

News Market Reaction

-1.92%

1 alert

-1.92% News Effect

On the day this news was published, AKRO declined 1.92%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 9:10 a.m. ET.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero’s lead product candidate, EFX, is currently being evaluated in three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH (F2-F3) or compensated cirrhosis (F4) due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the completed HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the ongoing SYMMETRY study in patients with compensated cirrhosis (F4) due to MASH, in which more than 300 patients have been treated with EFX or placebo for up to 96 weeks. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.

Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com

Media Contact:
Peg Rusconi
617.910.6217
peg.rusconi@deerfieldgroup.com

FAQ

When is Akero Therapeutics (AKRO) presenting at the Evercore ISI HealthCONx Conference 2024?

Akero Therapeutics will present at the conference on Tuesday, December 3, 2024, at 9:10 a.m. ET.

How can investors watch Akero Therapeutics' (AKRO) presentation at the HealthCONx Conference?

Investors can watch the presentation through a live webcast available on Akero's investor relations website at www.akerotx.com. An archived replay will also be available after the event.

What type of presentation will Akero Therapeutics (AKRO) give at the 2024 HealthCONx Conference?

Akero Therapeutics' management will participate in a fireside chat format presentation at the conference.

What is the focus area of Akero Therapeutics (AKRO) as presented in the announcement?

Akero Therapeutics is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases marked by high unmet medical need.